

Index

- abortive seizures, 474
 Abrams, Richard, 171, 173, 175
 ACC. *See* American College of Cardiology
 ACGME. *See* American Council on Graduate Medical Education
 acrogonine, 176
 ACT. *See* Association for Convulsive Therapy
 ACTH. *See* adrenocorticotrophic hormone
 activity regulated cytoskeleton (Arc) genes, 62–63
 acute catatonic schizophrenia, ECT for, 131–133
 benzodiazepines v. ECT for, 132, 133
 remission rates for, 132–133
 acute onset delirium, 435–436
 acute schizophrenia, ECT for, 127–131
 antipsychotic drugs v., 127–128
 remission rates for, 127
 trial studies for, 128–130, 131
Aden v. Younger, 210, 219
 adrenocorticotrophic hormone (ACTH), 153
 Advocates for Humanity, 217
 AF. *See* atrial fibrillation
 age of patient, ECT use and, 231
 in Asia, 260
 AHA. *See* American Heart Association
All's Well That Ends Well (Shakespeare), 384
 Almansi, Renato, 227
 Alonso, Rafael J. Larragoiti, 281
 ambulatory electroconvulsive therapy, 515–518
 ACT guidelines for, 516–517
 development of, 515–516
 ambulatory insulin therapy, 25
 American Academy of Child and Adolescent Psychiatry, 499
 American College of Cardiology (ACC), 402
 CAD/post-MI guidelines under, 404
 American Council on Graduate Medical Education (ACGME), 199–200
 American Heart Association (AHA), 402
 CAD/post-MI guidelines under, 404
American Journal of Psychiatry, 212, 413
 American Psychiatric Association (APA), xxi, 208
 ECT guidelines under, in state regulations, 202
 ECT Task Force under, 173, 200, 358, 516
 application guidelines under, 228
 with EEG, 468
 legislation influenced by, 214–215
 risk factor discussion guidelines of, 392
 Uruguay and, guidelines for ECT use in, 282
 amnesia. *See also* memory loss
 anterograde, 493
 retrograde, 491–492
An Angel at My Table (Frame), 182–183, 193
 anatomical theory, 78
 direct stimulation hypothesis in, 78
 TMS in, 78
 anesthesia, for ECT, 412–425
 airway management during, 422–423
 hyperventilation and, 423
 preparation procedures for, 422–423
 with LMA, 422
 anticholinergics, 414–415
 adverse effects of, 415
 atropine, 415
 glycopyrrolate, 414–415
 atracurium, 420–421
 in *The Bell Jar*, 413
 with concomitant medications, 423–424
 anticonvulsants, 423
 for glucose control, 424
 l-dopa, 424
 lithium, 423–424
 theophylline, 424
 history of, 413–414
 with curare, 413
 induction agents, 415–418
 barbiturates, 415–416
 comparisons between, 416
 etomidate, 417
 inhalational, 418
 ketamine, 417–418
 propofol, 417
 thiopental, 416–417
 ultrashort-acting narcotics, 418
 induction, in placebo trials, 113–114
 major elements of, 413

584 **Index**

- anesthesia, for ECT (*cont.*)
 with muscle relaxants, 418–421
 cuff method, 419
 mivacurium, 420
 moderate/short-acting, 420–421
 succinylcholine, 419–420
 rationale for, 412
 rocuronium, 421
- anesthetists, 323–324
 psychiatrists and, 324, 424–425
- anterograde amnesia, 493
- anticholinergics, 414–415
 adverse effects of, 415
 atropine, 415
 glycopyrrolate, 414–415
- anticoagulation, ECT and, 406
- anticonvulsant activity, from ECT, xxv
- anticonvulsant medications, 423
- anticonvulsant theory, 78
 seizure thresholds in, 78
- antidepressant medications
 for anxiety disorders, ECT v., 348–349
 with cECT, 505–506, 507–508
 electrode placement and, 433
 for mood disorders, ECT v., 114–115, 117
 blind v. nonblind studies for, 114–116
 dosage issues in, 116
 meta-analyses failures in, 117
 new medications in, 116
 with outmoded techniques, 116
 variability in diagnoses in, 116–117
 VNS as alternative to, 549
- anti-ECT movements, 212–214. *See also* Church of Scientology; Hubbard, Lafayette Ronald
- Coalition for the Abolition of Electroshock in, 214
- Coalition to Stop Electroshock in, 214, 215
- development of, 214
- Hubbard role in, 212–213
- Insane Liberation Front in, 214
- International Coalition for the Abolition of Electroshock in, 214
- Mental Patients Liberation Project in, 214
- NAPA in, 214, 215
- in Russian Federation, 268
- in Scandinavia, 237
- antipsychiatry opponents, ECT and, 198. *See also* Church of Scientology; Citizens Commission on Human Rights
- National Anti-Shock Action, 249
- U.S. state regulations and, influence on, 203–204
- antipsychotic drugs, xvii. *See also* hypofrontality
 for acute schizophrenia, 127–128
 for chronic schizophrenia, with ECT, 136–138
- death rates and, 371
- for depression, v. ECT, 351–352
- in DSM-IV, 363
- ECT v, xvii, 362–379
 for catatonia, 376–377
 for depression, 373–376
 hypofrontality and, 365–367
 lifespan rates and, 365
 physician behavior and, 377–379
 tardive psychosis and, 369
 therapeutic benefits with, 373–376
- for malignant catatonia, 133
- mortality rates with, 364
- for nonpsychotic indications, 363
- patient tolerance for, 372–373
 CATIE and, 372
- side effects of, 364
 aspiration pneumonia as, 371
 cancer as, 371–372
 cardiac risk factor exacerbation as, 370–371
 hypoactivity as, 372
 hypofrontality as, 365–367
 lifespan rates as, 364–365
 mental, 364, 369–370
 neurological, 370
 NMS as, 371
 sexual dysfunction as, 372
 sudden cardiac death as, 371
 tardive dyskinesia as, 370
 tardive psychosis as, 367–369
 with SSRIs, 375–376
- anxiety disorders, 342
- atypical depression and, 342
- bipolar disorder, xviii, 347
 non-ECT therapies for, 36–37
- ECT for, 343–344
 antidepressant medications v., 348–349
 patient selection for, 344
 for prevention of, 346–347
- indications for, 344–345
- OCD, 343
- PTSD, xviii, 345
- SSRIs for, 342
- tDCS for, 580
- apathetic syndrome, 366
- arachidonic acid cascade genes, 61–62
- Arc genes. *See* activity regulated cytoskeleton genes
- area under the curve (AUC), in prolactin release, 156
- Argentina, ECT use in, 280
- Arnold, William, 192
- Artaud, Antonin, 181–182

- Asia, ECT as treatment throughout, 256–264.
 See also Hong Kong, ECT use in; Japan, ECT use in; Taiwan, ECT use in; Thailand, ECT use in
 age as factor for, 260
 gender as factor for, 261
 history of, 256
 indications for, 259–260
 for schizophrenia, 259–260
 professional publications about, 263–264
 rates of use for, 256–259, 263
 regulation of, 262
 technical aspects of, 261–262
 with brief-pulse devices, 262
 electrode placement and, 261, 263
 modified with muscle relaxants, 261–262
 training guidelines for, 262–263
 aspiration pneumonia, 371
 Association for Convulsive Therapy (ACT), 516–517
 atracurium, 420–421
 atrial fibrillation (AF), 404–405
 atropine, 415
 atropinic agents, xxvi
 atypical depression, 342–346
 anxiety disorders and, 342
 AUC. *See* area under the curve, in prolactin release
 Auditory Hallucinations Rating Scale, 530
 Avrutsky, G.Y., 272
- Bailine, Samuel, 175
 Balloon Analog Risk Task, 578
 Barber, Stephen, 181
 barbiturates, 415–416
 BDNF pathway, 58–61
 after chronic ECS, 58–59
 neuritin gene, 61
 Vesl/homer gene, 60–61
A Beautiful Mind, 211
 Behrman, Andy, 190
 Belgium, ECT in, 246–248
 rate of use, 247–248
The Bell Jar (Plath), 184–185, 188, 193, 413
 Benchmark Method, 153, 441
 for peak heart rate, 479, 481
 for stimulus dosing, 456–458
 cardiovascular reactivity in, 458
 seizure morphology in, 457–458
 technique for, 456
 Bennett, Alan, 187–188, 194, 413
 benzodiazepines
 for acute catatonic schizophrenia, v. ECT, 132, 133
 ECT v., for catatonia, 376–377
 in pre-ECT protocols, xxvii
 bifrontal electrode placement, 442–444
 clinical outcomes from, 443
 MMSE scores after, 443–444
 Bini, Lucio, 227
 Bini, Luigi, 168
 bipolar depression, 530
 bipolar disorders, xviii
 cECT for, 511
 mECT for, 511
 non-ECT therapies for, 36–37
 bipolar mania, 531–532
 bitemporal electrode placement, 438–439
 Benchmark Method and, 153, 441
 clinical application of, 438
 clinical outcomes from, 438–439
 HRSD scores after, 438
 MMSE score after, 438
 right unilateral v., 440
 books and films, ECT in, 180–195, 211–212
 An Angel at My Table, 182–183, 193
 The Bell Jar, 184–185, 188, 193
 Electroboy, 190
 Family Life, 188
 Fear Strikes Out, 191–192, 193
 Frances, 188, 192
 Holiday of Darkness, 188–189
 legislation influenced by, 210–211
 Memoirs of an Amnesiac, 183
 One Flew over the Cuckoo's Nest, xviii, 172, 188, 191, 192, 210, 321
 Out of Tune, 193
 in professional literature, 211
 psychiatrists negatively influenced by, 198
 psychiatrists' portrayals in, 210
 Shadowland, 192
 Shine, 193
 Shock: The Healing Power of Electroconvulsive Therapy, 191
 The Snake Pit, 172
 The Tender Place, 184
 brain. *See also* deep brain stimulation
 DBS, 556–569
 advantages of, 559
 chronic, 557
 for depression, 561–562
 for dystonia, 557
 ethical considerations for, 566–568
 history of, 557
 neurophysiologic changes from, 558
 for OCD, 562
 patient selection for, 567–568
 principles of, 557–558
 quality standards for, 566–568

586 **Index**

- brain (*cont.*)
- safety of, 559
 - surgical implantation in, 557–558
 - target selection issues with, 560–561
 - for treatment-resistant depression, 556
- ECT and, electrical effects of, 6
- in choroid plexus, 58
 - in hippocampus, 55
- electricity effect on, overcoming inhibitions in, 82–85
- electroconvulsive therapy and, regions for, 45–46
- electrode placement and, neurobiology of, 436–438
- neuroimaging of, for ECT, 94–105
 - organizational levels of, 79–82
 - mental disorders and, 80–82, 89
- Brazil, ECT use in, 282–283
- history of, 282–283
- brief-pulse stimulus dose, 9–11
- approximation of separation in, 9
 - efficiency of, 13–14
 - electrode placement with, 10–11
 - pulse width in, 14
 - sine wave v., 12–13
 - ultrabrief, 14–15
 - average/range of, 15
 - electrode placement with, 14–15
- brief stimulus therapy (BST), 170–171
- BST. *See* brief stimulus therapy
- burns, ECT treatment with, 410
- CAD. *See* coronary artery disease
- caffeine, stimulus potentiation and, xxix
- Canada, ECT use in, 198–199
- cancer, from antipsychotic drugs, 371–372
- capacity. *See* mental capacity
- cardiovascular disorders, ECT with, 402
- anticoagulation and, 406
 - CAD, 404
 - ACC/AHA guidelines for, 404
 - medication treatment guidelines for, 404
 - CHF, 402–404
 - decompensated, 403
 - patient evaluation for, 403
 - treatment for,
 - dysrhythmias, 404–405
 - AF as, 404–405
 - ECG for, 405
 - ECG assessment with, 405
 - ICDs/pacemakers and, 405
 - MI, 404
 - ACC/AHA guidelines for, 404
 - medication treatment guidelines for, 404
 - valvular disease, 406
 - vascular disease, 405–406
- Cardiozol. *See* pentamethylenetetrazol, in non-ECT therapy
- Castedo, Cesar, 280
- catatonia
- childhood/adolescent psychoses and, 141–142
 - definition of, 124
 - in DSM-IV, 124
 - in ICD-10, 124
 - diagnostic problems with, 125
 - ECT for, 124–142
 - indications for, 349–350
 - for malignant, 133–135
 - methodological limitations of, 125–126
 - lethal, 350
 - malignant, ECT for, 133–135
 - antipsychotic drugs v., 133
 - NMS and, 133
 - “shock block” method of, 134
 - survival rates for, 134–135
 - organic, 139–141
 - pharmacological treatments for, 126
 - schizophrenia and, 124
 - acute, 131–133
 - TMS for, 531
- CATIE. *See* Clinical Antipsychotic Trials of Intervention Effectiveness
- Cavett, Dick, 180, 208
- CCHR. *See* Citizens Commission on Human Rights
- cECT. *See* continuation electroconvulsive therapy
- central nervous system (CNS), grand mal seizures and, xxiii
- cerebrovascular disease, ECT with, 408
- Cerletti, Ugo, 23, 168, 176, 227
- Chabasinski, Ted, 214
- chemical convulsants, 18–24. *See also* pentamethylenetetrazol, in non-ECT therapy
- with insulin therapy, 28–30
 - application procedures for, 29
 - complications from, 29–30
 - indications for, 29
 - “Meduna’s method” and, 266
 - model policy guidelines for, 292–294
 - for involuntary patients, 293–294
 - for voluntary patients, 292–293
 - in physical therapy, 167
 - PM-1090, 24
 - PTZ, 19–24
 - application procedure for, 19–20
 - complications from, 22–23
 - for depression, 21–22
 - ECT replacement for, 23–24
 - indications for, 20–22
 - relapse rates for, 21

- remission rates from, 20–21
 - for schizophrenia, 20–21
 - in Russian Federation, early use of, 266
- chemical convulsive therapy, 167
- CHF. *See* congestive heart failure, ECT with
- childhood/adolescent psychoses, catatonia and, 141–142
- children/adolescents, ECT in, 498–503
 - adverse events with, 502–503
 - tardive seizures, 502
 - cognitive effects of, 502–503
 - patient assessment for, 499–501
 - NICE guidelines for, 499
 - physical fitness as factor in, 500
 - treatment needs in, 499–500
 - rates of use for, 498–499
 - seizure thresholds with, 501
 - stimulus dosage for, 501–502
 - techniques for, 501–502
- Chile, ECT use in, 281
- choroid plexus, 58
- chromatin remodeling, 58
- chronic DBS, 557
- chronic schizophrenia, ECT for, 136–138
 - antipsychotic drugs and, 136–138
 - definition of, 136
 - effect of catatonic features after, 138
- Church of Scientology, 187, 208, 212, 217. *See also* Hubbard, Lafayette Ronald
 - CCHR and, 187, 208, 213
 - psychiatry and, 212
- Citizens Commission on Human Rights (CCHR), 187, 208, 213
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 372
- CME. *See* continual medical education
- CNS. *See* central nervous system
- Coalition for the Abolition of Electroshock, 214
- Coalition to Stop Electroshock, 214, 215
- Columbia University Consortium (CUC), 174
 - competency, 393–394
 - determination of, 393
 - legally relevant criteria for, 395–396
 - MacCAT-T for, 393
- congestive heart failure (CHF), ECT with, 402–404
 - decompensated, 403
 - patient evaluation for, 403
 - treatment for,
- Consortium for Research in ECT (CORE), 174
 - mECT study by, 520
- constant-current stimulus generators, 4–5
 - skin burns from, 4–5
- constant-current tDCS, 581
- constant-voltage stimulus generators, 4
- continual medical education (CME), 205
- continuation electroconvulsive therapy (cECT), 505–512
 - for bipolar disorders, 511
 - for depression, 505–510, 511
 - with antidepressants, 505–506, 507–508
 - indications for, 510
 - with lithium, 507
 - praxis of, 510–511
 - for schizophrenia, 511
- The Convulsive Therapy of Schizophrenia* (Rotshtein), 266
- convulsive therapy, 168
 - reemergence of, 175–176
- CORE. *See* Consortium for Research in ECT
- coronary artery disease (CAD), 404
 - ACC/AHA guidelines for, 404
 - medication treatment guidelines for, 404
- corticotropin-releasing hormone (CRH), 478
- cortisol hormone release, 159–160
 - causes of, 159
 - pretreatment for, 159
 - resting hypercortisolism and, 159
- Cott, Jonathan, 190–191, 194
- court-ordered treatment, 397
 - PADs and, 397
 - POA and, 397
- craving disorders, 578–579
- CREB pathway, 58–61
 - ECS and, 60
- CRH. *See* corticotropin-releasing hormone
- Cuba, ECT use in, 281
- CUC. *See* Columbia University Consortium
- cuff method, 419
- curare, 23
 - as anesthesia, 413
- DBS. *See* deep brain stimulation
- deep brain stimulation (DBS), 556–569
 - advantages of, 559
 - chronic, 557
 - for depression, 561–562
 - neurobiology of, 559–560
 - studies for, 563
 - for dystonia, 557
 - ethical considerations for, 566–568
 - history of, 557
 - neurophysiologic changes from, 558
 - for OCD, 562
 - neurobiology of, 560
 - studies for, 564
 - patient selection for, 567–568
 - exclusion criteria for, 567–568
 - inclusion criteria for, 567
 - principles of, 557–558
 - quality standards for, 566–568
 - patient management in, 568

588 **Index**

- deep brain stimulation (DBS) (*cont.*)
 safety of, 559
 surgical implantation in, 557–558
 target selection issues with, 560–561
 for treatment-resistant depression, 556
 deep transcranial magnetic stimulation,
 536–537
 de Haviland, Olivia, 172
 d’Elia, Giacomo, 237
 delusions
 with melancholia, 352–353
 from TMS therapy, 536
 dementia, ECT with, 407
 medication-resistant, 357–358
 medication treatments with, 407
 Denmark. *See* Scandinavia, ECT as treatment
 in
 depolarization, 7
 depression
 antidepressant-resistant, 352–354
 atypical, 342–346
 anxiety disorders and, 342
 brain stimulation applications for, 68
 cECT for, 505–510, 511
 with antidepressants, 505–506, 507–508
 indications for, 510
 with lithium, 507
 praxis of, 510–511
 DBS for, 561–562
 studies for, 563
 diagnostic criteria for, 341
 diencephalic theory and, 77
 in DSM-IV, 341
 ECT for, 45, 109
 antipsychotic drugs v., 373–376
 antipsychotic medications v., 351–352
 for atypical, 342–346
 cECT after, 505–510, 511
 functional consequences of, 85
 neurotransmitters and, effects on, 46
 receptors and, effects on, 46
 in U.S., as treatment for, 228–229
 hippocampal volume and, 65–66
 HRSD for, 103, 345–346
 for resting hypercortisolism, 160
 indications for, 345
 MDD, 489
 VNS for, 547
 melancholia and, 347
 delusions with, 352–353
 ECT for, 347–348, 351
 psychotic, 353
 monoamine depletion and, 46
 Montgomery-Asberg Depression Rating Scale
 for, 346
 NE and, 49–51
 neurobiology of, 559–560
 NPY neuropeptide and, 53
 PTZ for, in non-ECT therapy, 21–22
 resting hypercortisolism and, 160
 HRSD scores for, 160
 serotonergic pathways and, 47–49
 serotonin in, 47–49
 STAR*D study for, 556
 stimulus dosing for, 450–454, 455–456
 fixed, 454
 formula-based, 453–454
 mECT and, 460–461
 titrated, 450–453
 suicidality and, 348
 tDCS for, 576–577
 TMS for, 528–529
 bipolar, 530
 high-frequency, 529
 low-frequency, 529
 treatment-resistant, 172–173
 DBS for, 556
 VNS for, 543
 VNS for, 546–548
 clinical outcomes for, 547
 MDD, 547
 treatment-resistant, 549
 trial studies for, 547–548
 diabetes mellitus, ECT with, 410
 glucose control medications and, 424
*The Diagnostic Statistical Manual of Mental
 Disorders, 4th Edition (DSM-IV-TR)*,
 124
 antipsychotic drugs in, 363
 depression diagnosis in, 341
 treatment-resistant depression in, 549
 melancholia diagnosis in, 347
Dianetics (Hubbard), 212
 Dianetics, as spiritual technology, 212
 as alternative to psychiatry, 213
 diencephalic theory, 77–78
 depression and, 77
 diffusion tensor imaging (DTI), 94
 during interictal period, with ECT, 105
 diffusion weighted imaging (DWI), 96
 during interictal period, with ECT, 105
 direct stimulation hypothesis, in anatomical
 theory, 78
 Disconn-ECT News, 217
 disorders. *See* anxiety disorders; bipolar
 disorders; cardiovascular disorders, ECT
 with; craving disorders; major depressive
 disorder; mental disorders; mood
 disorders; movement disorders, ECT
 with; obsessive-compulsive disorder;
 panic disorder; schizoaffective disorders,
 ECT for

- Donahue, Anne B., 194
- dopamine hypothesis, 76. *See also* schizophrenia
- dopaminergic pathways, 51
- dopamines, 51
- dopamines, 51
- after ECS, 51
- HVA, 51
- hypothesis, 76
- receptors, 51
- drugs, antipsychotic, xvii
- “dry shock,” 33
- DSM-IV-TR. *See The Diagnostic Statistical manual of Mental Disorders, 4th Edition*
- DTI. *See* diffusion tensor imaging
- Dukakis, Kitty, 191, 194, 208, 212
- Dukakis, Michael, 208
- Duke, Patty, 208
- Dutch Association for Psychiatry, 249
- DWI. *See* diffusion weighted imaging
- dysexecutive syndrome, 366
- dysrhythmias, with ECT, 404–405
- AF as, 404–405
- ECG for, 405
- dysthymic order, 530
- dystonia, 557
- EAAC1. *See* excitatory amino acid carrier 1
- ECG. *See* electrocardiogram, with ECT
- echocardiograms (ECG), with ECT
- for cardiovascular disorders,
- for dysrhythmias, 405
- ECS. *See* electroconvulsive shock
- ECT Accreditation Service (ECTAS), 241
- ECTAS. *See* ECT Accreditation Service
- ECT Handbook*, 239, 241–242
- EEG. *See* electroencephalography, with ECT
- EFFECT, 252
- electricity
- ECT and, 3–15
- on brain tissue, 6
- brief-pulse stimulus dose and, 9–11, 12–13
- conversion of energy in, 3
- dynamic impedance and, 6
- seizure generation and, 6–8
- sine wave stimulus dose and, 11, 12–13
- stimulus efficiency in, 3
- stimulus generators, 4–5
- toxic dosage range with, 5–6
- hypothesized mechanisms of action, for ECT, and, 82–89
- overcoming inhibitions in brain and, 82–85
- process of, 3
- properties of, 3–4
- seizure induction and, 6–8, 82
- Electroboy* (Behrman), 190
- electrocardiogram (ECG), with ECT, 468
- electroconvulsive shock (ECS), 45
- BDNF pathway and, 58–59
- CREB pathway and, 60
- dopamines after, 51
- 5-HT serotonin receptors after, 47–49
- GABA pathways and, 51–52
- gene regulation after, 56
- gene transcription after, 54–55
- with MI, 404
- NE receptors, 50–51
- neurogenesis after, 64–66, 67
- regulation of, 65, 66–67
- NPY neuropeptide after, 53
- serotonins after, 47–49
- synaptic plasticity after, 64–66, 67
- neurotrophic factors for, 67
- structural changes, 65
- tachykinin neuropeptides after, 54
- electroconvulsive therapy (ECT). *See also*
- anesthesia, for ECT; anti-ECT
- movements; Asia, ECT as treatment
- throughout; books and films, ECT in;
- brief-pulse stimulus dose;
- children/adolescents, ECT in;
- electroconvulsive shock;
- electroconvulsive therapy; electrodes,
- placement of; electroencephalography,
- with ECT; gene transcription, ECT
- effects on; hormones, ECT effect on;
- hypothesized mechanisms of action, for
- ECT; informed consent, for ECT;
- legislation, for ECT use; neuroimaging,
- for ECT; neuropeptides, ECT effects on;
- neurotransmitters, ECT effects on;
- nonelectrical convulsive therapies;
- physical therapies; psychiatric hospital
- programs, ECT in; psychosis, ECT for;
- seizures; sine wave stimulus dose;
- stimulus dosing, with ECT; stimulus
- generators
- for acute schizophrenia, 127–131
- antipsychotic drugs v., 127–128
- remission rates for, 127
- trial studies for, 128–130, 131
- ambulatory, 515–518
- ACT guidelines for, 516–517
- development of, 515–516
- analogous to surgery, xviii
- anesthesia for, 412–425
- airway management during, 422–423
- with anticholinergics, 414–415
- with atracurium, 420–421
- in *The Bell Jar*, 413
- with concomitant medications, 423–424
- history of, 413–414
- induction agents, 415–418

- electroconvulsive therapy (ECT) (*cont.*)
 induction, in placebo trials, 113–114
 major elements of, 413
 with muscle relaxants, 418–421
 rationale for, 412
 rocuronium, 421
- anterograde amnesia after, 493
- antidepressants v., 114–115, 117, 348–349
 blind v. nonblind studies for, 114–116
 dosage issues in, 116
 meta-analyses failures in, 117
 new medications in, 116
 with outmoded techniques, 116
 variability in diagnoses in, 116–117
- anti-ECT movements, 212–214
 development of, 214
 in Russian Federation, 268
 in Scandinavia, 237
- antipsychiatry opponents and, 198
 U.S. state regulations and, influence on, 203–204
- antipsychotic drugs v., xvii, 362–379
 for catatonia, 376–377
 for depression, 373–376
 hypofrontality and, 365–367
 lifespan rates and, 365
 physician behavior and, 377–379
 tardive psychosis and, 369
 therapeutic benefits with, 373–376
- for anxiety disorders, 343–344
 antidepressants v., 348–349
 indications for, 344–345
 patient selection for, 344
 for prevention of, 346–347
- APA Task Force on, 173, 200, 358, 516
 guidelines under, 202
- in Argentina, 280
- throughout Asia, 256–264
 age as factor for, 260
 gender as factor for, 261
 history of, 256
 indications for, 259–260
 professional publications about, 263–264
 rates of use for, 256–259, 263
 regulation of, 262
 technical aspects of, 261–262
 training guidelines for, 262–263
- in Belgium, 246–248
- benzodiazepines v., for catatonia, 376–377
- in books and films, 180–195
An Angel at My Table, 182–183, 193
The Bell Jar, 184–185, 188, 193
Electroboy, 190
Family Life, 188
Fear Strikes Out, 191–192, 193
Frances, 188, 192
Holiday of Darkness, 188–189
Memoirs of an Amnesiac, 183
One Flew over the Cuckoo's Nest, xviii, 172, 188, 191, 192, 210, 321
Out of Tune, 193
Shadowland, 192
Shine, 193
Shock: The Healing Power of Electroconvulsive Therapy, 191
The Snake Pit, 172
The Tender Place, 184
- brain regions for, 45–46
- in Brazil, 282–283
 history of, 282–283
- with burns, 410
- with CAD, 404
- in Canada, as treatment therapy, 198–199
- for catatonia, 124–142
 indications for, 349–350
 lethal, 350
 malignant, 133–135
 methodological limitations of, 125–126
 organic, 139–141
- cECT after, 505–512
 for bipolar disorders, 511
 for depression, 505–510, 511
 for schizophrenia, 511
- for cerebrovascular disease, 408
- with CHF, 402–403, 404
- in children/adolescents, 498–503
 adverse events with, 502–503
 cognitive effects of, 502–503
 patient assessment for, 499–501
 rates of use for, 498–499
 seizure thresholds with, 501
 stimulus dosage for, 501–502
 techniques for, 501–502
- in Chile, 281
- for chronic schizophrenia, 136–138
 antipsychotic drugs and, 136–138
 definition of, 136
 effect of catatonic features after, 138
- clinical indications for, 341–358
 for catatonia, 349–350
 for delusions, 352–353
 for depression, 345
 for lethal catatonia, 350
 for mixed manic-depressive episodes, 350
- cognitive side effects of, 485–495
 to executive functions, 493–494
 to language function, 494–495
 memory loss as, 490–493
 postictal confusion/disorientation, 486–487
- in Cuba, 281

- for dementia, 357–358, 407
 - medication-resistant, 357–358
 - medication treatments with, 407
- for depression, 45, 109
 - antidepressant-resistant, 352–354
 - antipsychotic medications v., 351–352
 - for atypical, 342–346
 - brain stimulation applications for, 68
 - cECT for, 505–511
 - functional consequences of, 85
 - neurotransmitters and, effects on, 46
 - receptors and, effects on, 46
 - with diabetes mellitus, 410
 - with dysrhythmias, 404–405
 - with ECG, 405, 468
- ECS in, 45
 - BDNF pathway and, 58–59
 - CREB pathway and, 60
 - dopamines after, 51
 - 5-HT serotonin receptors after, 47–49
 - GABA pathways and, 51–52
 - gene regulation after, 56
 - gene transcription after, 54–55
 - NE receptors, 50–51
 - neurogenesis after, 64–67
 - NPY neuropeptide after, 53
 - serotonins after, 47–49
 - synaptic plasticity and, 64–67
 - tachykinin neuropeptides after, 54
- EEG with, 96, 468–474
 - APA Task Force guidelines for, 468
 - electrode placement and, 468–469
 - of HR, 479
 - during ictal periods, 469–472
 - memory loss and, 472–473
 - during postictal periods, 470–471
 - seizures and, 473–474
- electricity and, 3–15
 - on brain tissue, 6
 - brief-pulse stimulus dose and, 9–11, 12–13
 - conversion of energy in, 3
 - dynamic impedance and, 6
 - seizures from, 6–8
 - sine wave stimulus dose and, 11, 12–13
 - stimulus generators, 4–5
 - toxic dosage range with, 5–6
- electrode placement in, 430–444
 - antidepressant medication and, 433
 - in Asia, 261, 263
 - bifrontal, 442–444
 - bitemporal, 438–439
 - with brief-pulse stimulus dose, 10–11
 - cognitive side effects from, 434–436
 - comparison studies for, 433
 - development history for, 170, 173–175
 - efficacy of, 434
 - in Europe, 252
 - LART technique for, 175, 441–442
 - neurobiology of, 436–438
 - pre-ECT protocol for, xxviii
 - right unilateral, 439–441
 - SSRIs and, 433
 - with stimulus dosing, 459–460
 - with ultrabrief-pulse stimulus dose, 14–15
- with epilepsy, 409
- in Europe, 246
 - EFFECT for, 252
 - electrode placement variation in, 252
 - history in, 246
- throughout Europe, 246
 - history in, 246
- evaluation after, 505–512
- fractures as result of, 209
- in France, 248
- Friedberg opposition to, 213–214
- future applications of, 176
- in Germany, 248–249
- history of, 167–176
 - current application reduction in, 170–171
 - electrode placement in, 170, 173–175
 - Meduna in, 18, 168
 - memory loss in, 169
 - oxygenation in, 171–172
 - within physical therapies, 167
 - psychopharmacology in, 172
 - restraint development in, 169
- Sakel in, 18, 167–168
- in Hong Kong, 256
- hormonal effects of, 149–161
 - ACTH, 153
 - comparison of changes in, 151–153
 - consequences of, 150–151
 - cortisol release, 159–160
 - future research applications with, 160–161
 - posterior pituitary, 158–159
 - prolactin, 152, 153–158
 - resting hypercortisolism and, 159
 - as temporary, 149
- in hospital programs, 201
 - model policy guidelines for, 287–294, 313
 - for patients from other facilities, 306–308
- HR and, 477–483
 - peak, 479–481
 - seizure activity and, 477–479
 - tachycardia duration and, 481–483
- Hubbard movement against use of, 212, 213
- hypothesized mechanisms of action for, 75, 76–90
 - abnormal metabolism in, 85
 - anatomical theory of, 78

592 **Index**

- electroconvulsive therapy (ECT) (*cont.*)
- anticonvulsant theory of, 78
 - background of, 75
 - development of, 79–89
 - diencephalic theory of, 77–78
 - functional consequences of, 85–87
 - neurochemical theories of, 75–77
 - neuronal network function restoration in, 87–89
 - seizure generalization theory and, 79, 89
- with ICDs/pacemakers, 405
- in India, 258
- informed consent for, xxv–xxvi, 384–398
- competency for, 393–394
 - court-ordered treatment and, 397
 - definitions of, 385
 - discussion strategies for, 387–392
 - historical development of, 385
 - hospital programs policy guidelines for, 289–292
 - in Latin America, 279–280
 - legislation on, for ECT use, 215
 - mental capacity for, 393–394
 - mental incapacity and, 393–397
 - obstacles to, 392–397
 - practical strategy methods for, 386–387
- in Japan, 257–258
- throughout Latin America, 276–283
- anesthesia with, 279
 - applications of, 278–279
 - history of use in, 276–277
 - informed consent for, 279–280
 - rates of, 279
 - techniques for, 279
 - training for, 280
- legislation for, 207–220
- APA Task Force role in, 214–215
 - for banned use, 208
 - in California, 214–216
 - constructive lawmaking in, 218–219
 - films' influence on, 210–211
 - history of, 214–218
 - for informed consent, 215
 - litigation cases as basis for, 209–210
 - in Massachusetts, 215
 - proactive, 219
 - state regulations and, 202–204, 233
 - in Texas, 216–218
- legislative regulations against, 202–204
- for malignant catatonia, 133–135
- antipsychotic drugs v., 133
 - NMS and, 133
 - “shock-block” method of, 134
 - survival rates for, 134–135
- malpractice concerns with, 204
- mania, 119–120
- for manic episodes, 354
- MECT and, 138–139, 518–522
- for bipolar disorders, 511
 - cognitive function during, 521–522
 - CORE study on, 520
 - definition of, 518
 - effectiveness of, 520
 - electrode placement during, 522
 - NICE on, 519–520
 - pharmacotherapy with, 520–521
 - relapse rates for, 519
 - for schizoaffective disorders, 135
 - with stimulus dosing, 460–461, 522
- with medical disorders, 401–410
- anticoagulation and, 406
 - CAD, 404
 - for cardiovascular disorders, 402
 - cerebrovascular disease, 408
 - CHF, 402–404
 - dementia, 407
 - diabetes mellitus, 410
 - dysrhythmias, 404–405
 - epilepsy, 409
 - with ICDs/pacemakers, 405
 - intracranial space-occupying lesions, 409
 - MI, 404
 - neurological, 406–407
 - planned management for, 401
 - pretreatment assessment for, 401
 - pulmonary, 410
 - reevaluation during treatment in, 401
 - valvular disease, 406
 - vascular disease, 405–406
- for melancholia, 347–348, 351
- with multiple medications, 348
 - psychotic, 353
 - SSRIs v., 347–348
- for mental disorders, 89
- in Mexico, 281–282
- with MI, 404
- for mood disorders, 109–120
- antidepressant medications v., 114–115, 117
 - mania, 119–120
 - placebo trials v., 109–112, 114
 - response rates for, 109, 110
 - variety of treatments in, 117
- as most clinically studied procedure, 197–198
- for movement disorders, 407–408
- PD, 407–408
- muscle relaxants with, 170
- negative public impressions of, xviii, 172
- from *One Flew over the Cuckoo's Nest*, xviii, 172

- in The Netherlands, 249, 250
- neurochemical effects of, 45–69
 - on dopaminergic pathways, 41
 - on GABA pathways, 51–52
 - on gene transcription, 54–64
 - on glutamergic systems, 52
 - on neuropeptides, 52–54
 - on neurotransmitters, 46–52
 - on noradrenergic pathways, 49–51
 - on receptors, 46–52
 - on serotonergic pathways, 47–49
- neuroimaging and, 94–105
 - with DTI, 94
 - with DWI, 96
 - with EEG, 96
 - future applications for, 105–106
 - during ictal period, 96–98
 - during interictal period, 99–105
 - with LORETA, 96
 - measurement parameters for, 95–96
 - with MRI, 94, 95–96
 - with MRS, 94
 - with PET, 94
 - during postictal periods, 99–101
 - purpose of, 94–95
 - with SPECT, 94
 - structural abnormalities under, 94
 - with TCD, 96
- non-ECT therapies, 17–37
 - for bipolar disorder, 36–37
 - chemical convulsants, 18–24
 - flurothyl inhalation, 30–31
 - historical background of, 17–18
 - insulin therapy, after coma inducement, 18, 24–28
 - PTZ, 19–24
 - theoretical implications of, 31–37
- nursing guidelines for, 300–306
 - inpatient transportation, 301–302
 - for post-ECT duties, 305–306
 - pre-ECT patient preparation, 301
 - for recovery procedures, 304–305
 - staff assistance during treatment, 303–304
 - treatment room preparation, 302
- orbitofrontal syndrome from, 367
- for organic catatonia, 139–141
- in Pakistan, 258
- patient selection for, 341–358
 - for anxiety disorders, 344
 - with PD, 407–408
- personal accounts of, 181–184, 187, 189–191
- philosophy for use of, 341–342
- physical suite layout for, 314–321
 - anesthetists in, 323–324
 - design considerations for, 321
 - for high-volume operations, 316
 - IV access considerations in, 317–319
 - nurses in, 322–323
 - outpatient considerations for, 319
 - pretreatment personnel in, 322
 - psychiatrists in, 323
 - for recovery rooms, 320–321
 - in small hospitals, 315–316
 - for small-volume operations, 315–316
 - surgical operating rooms and, 314
 - for treatment rooms, 319–320
- Plath critique of, 184–185, 211
- in Portugal, 250–251
- posttreatment protocol, xxix–xxx
 - patient discharge considerations in, xxix–xxx
 - patient management in, xxix
- pre-ECT protocol, xxv–xxx
 - atropinic agents in, xxvi
 - with benzodiazepines, xxvii
 - electrode placement in, xxviii
 - intramuscular medication in, xxv–xxvi
 - muscle relaxants in, xxvii
 - narcosis agents in, xxvi–xxvii
 - oral medications in,
 - oxygenation during, xxvii
 - physiological monitoring for, xxix
 - sedation for sleep on night before, xxvi
 - stimulus dose method in, xxviii
 - stimulus potentiation in, xxviii–xxix
- during pregnancy, 409
- as prerequisite for other procedures, 357
- prevention of mental illness, xvii
- for prevention of threatening experiences, xvii–xviii
 - bipolar disorders, xviii
 - PTSD, xviii
- psychiatrists' response to, 197–205
 - in Canada, 198–199
 - legislative regulations against, 202–204
 - malpractice concerns, 204
 - as molded by negative film portrayals, 198
 - as professional mindset, 204–205
 - sociopolitical barriers to, 201–202
 - training issues with, 199–200
 - in treatment patterns, 198, 200–201
 - in U.S., 198–199
- psychological testing after, 485–490
 - of general intelligence, 487–490
 - with MMSE, 435, 485–486
 - with SSMQ, 491
 - with WAIS, 488
- for psychosis, 350
 - medication-resistant, 354–357
- PTZ replacement by, 23–24
- public perceptions of, 208

- electroconvulsive therapy (ECT) (*cont.*)
- reboot theory of, xxiii–xxv
 - anticonvulsant activity in, xxv
 - preexisting psychiatric illness in, xxiii
 - seizures' role in, xxiii
 - recovery from, xxix
 - in regional medical centers, guidelines for, 308–311
 - reporting requirements for, 311
 - retrograde amnesia after, 491–492
 - in Russian Federation, 266–273
 - anti-ECT movement in, 268
 - chemical convulsants and, in early use of, 266
 - contemporary applications of, 271–272
 - device development in, 271
 - early history of, 266–270
 - “Meduna’s method” and, 266
 - Moscow Society of Neurologists and Psychiatrists in, 270
 - for nonpsychiatric conditions, 272
 - political influence on, 267–268
 - psychiatry in, under Stalin, 267
 - Soviet Scientific Society of Neurologists and Psychiatrists in, 268
 - in Scandinavia, 236–238
 - anti-ECT movement in, 237
 - future applications for, 243
 - history of, 236
 - rates of use for, 236–237
 - research tradition and, 238
 - training for, 242
 - for schizoaffective disorders, 135–136
 - psychosis and, 355
 - for schizophrenia, 124–131, 142
 - acute, 127–131
 - acute catatonic, 131–133
 - chronic, 136–138
 - continuation, 138–139
 - history of, 124–125
 - mECT and, 135, 138–139
 - methodological limitations of, 125–126
 - for schizoaffective disorders, 135–136
 - for schizophreniform disorder, 126–127
 - for schizophreniform disorder, 126–127
 - seizures from, repeated application
 - complications for, 35–36
 - spontaneous v., 82–84
 - “shock-block” method of, 134
 - sociopolitical barriers to, 201–202
 - in Spain, 251
 - with spinal cord injury, 410
 - stimulus dosing with, 447–463
 - augmentation strategies for, 458–459
 - Benchmark Method for, 456–458
 - case studies of, 461–463
 - cognitive side effects of, 454–455
 - for depression, 450–454, 455–456
 - electrode placement and, 459–460
 - with mECT, 460–461, 522
 - schedule for, 452
 - sham studies for, 449
 - units of measure for, 447–449
 - waveform morphology for, 449–450
 - in Taiwan, 256–257
 - tardive psychosis for, 369
 - in Thailand, 257
 - TMS v., 36, 534–535
 - training issues with, 199–200
 - for nonpsychiatric physicians, 199
 - during psychiatric residency, 199–200
 - treatment for, xviii
 - in UK, 238–242
 - contemporary standards and practices for, 241–242
 - ECT Handbook* in, 239, 241–242
 - future applications for, 243
 - under NICE, 240–241
 - pre-NICE standards and practices, 238–240
 - training for, 242–243
 - in Uruguay, 282
 - in U.S., 198–199, 209–210, 227–234
 - academic medical centers as factor for, 229
 - age as factor for, 231
 - APA guidelines for, 228
 - demographic variation in, 231–232
 - for depression, 228–229
 - ethnicity/race as factor in, 232
 - excessive use of, 209
 - future applications for, 233–234
 - gender as factor in, 231–232
 - inpatient v. outpatient status and, 230–231
 - insurance access as factor for, 232–233
 - legislation for, 207–220
 - litigation over, 209–210
 - overuse of, 209
 - in public v. private hospitals, 230
 - regional/state variation for, 229
 - service sites for, 230–231
 - service system variation for, 229–230
 - small-area analysis for, 228–229
 - socioeconomic factors for, 232–233
 - state regulations over, 202–204, 233
 - usage trends for, 227
 - variation of, 228
 - with VNS, 549–550
 - electrodes, placement of, 430–444
 - antidepressant medication and, 433
 - in Asia, in ECT treatment, 261, 263
 - bifrontal, 442–444
 - clinical outcomes from, 443
 - MMSE scores after, 443–444

- bitemporal, 438–439
 Benchmark Method and, 153, 441
 clinical application of, 438
 clinical outcomes from, 438–439
 HRSD scores after, 438
 MMSE score after, 438
 right unilateral v., 440
 with brief-pulse stimulus dose, 10–11
 cognitive side effects from, 434–436
 acute onset delirium as, 435–436
 gradual cumulative disorientation as, 435
 MMSE and, 435
 permanent memory loss as, 436
 comparison studies for, 433
 development of, in ECT history, 170, 173–175
 CUC v. CORE study in, 174
 EEG and, 468–469
 efficacy of, 434
 stimulus dosing as factor for, 434
 in Europe, in ECT treatment, 252
 LART technique, 175, 441–442
 clinical applications of, 441
 MMSE scores after, 442
 during MECT, 522
 neurobiology of, 436–438
 through skull bones, 437
 in pre-ECT protocol, xxviii
 right unilateral, 439–441
 bitemporal v., 440
 clinical application of, 439
 dosing levels for, 440–441
 rationale for, 439
 SSRIs and, 433
 with stimulus dosing, 459–460
 in tCDS, 575
 with ultrabrief-pulse stimulus dose, 14–15
 electroencephalography (EEG), with ECT, 96, 468–474
 APA Task Force guidelines for, 468
 electrode placement and, 468–469
 of HR, 479
 during ictal periods, 469–472
 interpretation of, 471–472
 scalp distribution of, 471
 seizure duration during, 471
 seizure expression during, 471–472
 seizure rhythms during, 470
 memory loss and, 472–473
 during postictal periods, 470–471
 seizures and, 473–474
 abortive, 474
 missed, 473–474
 prolonged, 474
Electroshock: The Case Against (Morgan), 212
 ELL2 gene, 64
 emergence agitation, 150. *See also* postictal excitement
 Emergency Medical Treatment and Active Labor Act (EMTALA), 287
 EMTALA. *See* Emergency Medical Treatment and Active Labor Act
 Endler, Norman, 188–189
 England. *See* United Kingdom, ECT as treatment in
 epilepsy
 ECT with, 409
 phenytoin for, 35
 schizophrenia and, 34–35
 tDCS for, 577–578
 VNS for, 543, 546
 epileptic seizures, 84
 epileptiform phenomena, 33
 symptoms of, 34
 epinephrine, 478
 ERK5 genes, 63
 ethnicity, ECT use and, 232
 etomidate, 417
 eugenics
 psychiatrists and, 17
 schizophrenia and, 17
 Europe, ECT treatment throughout, 246. *See also* Belgium; France; Germany; The Netherlands; Portugal, ECT use in; Spain, ECT use in
 EFFECT for, 252
 electrode placement variation in, 252
 history in, 246
 excitatory amino acid carrier 1 (EAAC1), 52
Family Life, 188
 FDA. *See* Food and Drug Administration
Fear Strikes Out, 191–192, 193
 FGF-2 genes, 62
 fibromyalgia, 577
 films, ECT in. *See* books and films, ECT in
 Fink, Max, 173, 174, 238
 Finland. *See* Scandinavia, ECT as treatment in
 First International Meeting on Modern Treatment of Schizophrenia, 18
 5-HT serotonin receptors, 47–49
 fixed-charge stimulus generators, 4
 flurothyl inhalation therapy, 30–31
 application procedures for, 30
 complications from, 30–31
 from technical issues, 30–31
 historical background for, 30
 indications for, 30
 seizure onset with, 30

- fMRI. *See* functional magnetic resonance imaging
- Fontanarrosa, Orlando y, 280
- Food and Drug Administration (FDA), 287
- Forman, Milos, xviii, 172
- Foucault, Michel, 172
- fractures, from ECT, 209
- Frame, Janet, 182–183, 193
- France, ECT in, 248
- training issues with, 248
- Frances, 188, 192
- Frank, Leonard Roy, 214
- Friedberg, John, 211, 212
- opposition to ECT, 213–214
- Friedman, Emerick, 170
- frizzled protein (Frz) genes, 64
- Frz genes. *See* frizzled protein genes
- functional magnetic resonance imaging (fMRI), 96
- GABA. *See* gamma-aminobutyric acid pathways
- Gage, Phineas, 366
- Gamito, António, 233
- gamma-aminobutyric acid (GABA) pathways, 46, 51–52
- ECS and, 51–52
- ECT and, 51–52
- in hypothesized mechanisms of action, for ECT, 85–86
- Geddes, John, 174
- gender, ECT use by, 231–232
- in Asia, 261
- gene transcription, ECT effects on, 54–64. *See also* BDNF pathway
- arachidonic acid cascade genes, 61–62
- Arc genes, 62–63
- in BDNF/CREB pathway, 58–61
- chronic ECS and, 58–59, 60
- in choroid plexus, 58
- for chromatin remodeling, 58
- after chronic ECS, 54–55
- after ECS, 56
- ELL2 gene, 64
- ERK5/MEF2C genes, 63
- FGF-2 genes, 62
- Frz genes, 64
- in hippocampus, 55
- Kf-1 gene, 64
- Ndr2 gene, 64
- neurochemical theories and, 76–77
- neurogenesis, 64–67
- regulation of, 65, 66–67
- NGF genes, 62
- synaptic plasticity, 64–67
- neurotrophic factors for, 64–67
- structural changes, 65
- TIMP-1 and, 63
- TRH and, 63
- VAMP2 gene, 64
- VEGF genes, 62
- VGF genes, 62
- Germany, ECT in, 248–249
- increased use of, 249
- Glassman, Alexander, 173
- glucagon, 25
- glutamergic systems, 52
- EAAC1, 52
- glycopyrrolate, 414–415
- Goldman, Douglas, 171
- Gonda, Victor, 169
- gradual cumulative disorientation, 435
- grand mal seizures, xxiii–xxiv
- CNS depletion in, xxiii
- Grove, Andrew, 362
- Guidelines of Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery* (ACC/AHA), 402
- Halstead-Reitan Neuropsychological Test Battery, 494
- Hamilton, Max, 419
- Hamilton Rating Scale for Depression (HRSD), 103, 345–346, 489
- after bimodal electrode placement, 438
- in placebo trials v. ECT, for mood disorders, 110–113
- Hammersley, Donald, 173
- heart rate (HR), ECT and, 477–483
- peak, 479–481
- Benchmark Method for, 479, 481
- hyperventilation from, 480
- seizure activity and, 477–479
- CRH and, 478
- EEG recording of, 479
- epinephrine and, 478
- neuroanatomic rationale for, 477–478
- tachycardia duration and, 481–483
- Helfgott, David, 193
- Helfgott, Margaret, 193
- Hemingway, Ernest, 180, 184, 185–186
- Hotchner on, 186–187
- suicide attempts of, 185–187
- hippocampus, 55
- depression and, volume as factor in, 65–66
- The History of Madness* (Foucault), 172
- Holiday of Darkness* (Endler), 188–189
- Holmberg, Carl Gunnar, 170, 413
- homovanillic acid (HVA), 51
- Hong Kong, ECT use in, 256
- hormones, ECT effect on, 149–161
- ACTH, 153
- comparison of changes in, 151–153

- for baseline levels, 152–153
- Benchmark Method for, 153
- measurement problems in, 151
- medical v. psychiatric, 152
- consequences of, 150–151
- postictal excitement as, 150–151
- during pregnancy, 151
- cortisol release, 159–160
- causes of, 159
- pretreatment for, 159
- future research applications with, 160–161
- posterior pituitary, 158–159
- oxytocin, 158–159
- vasopressin, 158–159
- prolactin, 152, 153–158
- AUC and, 156
- basic model for, 156–157
- brain neurochemistry changes and, 154
- as pituitary hormone archetype, 154–155
- seizure-induced, 158
- resting hypercortisolism and, 159
- cognitive side effects of, 160
- depression and, 160
- as temporary, 149
- Horowitz, Vladimir, 181, 208
- hospitals. *See* psychiatric hospital programs, ECT in
- Hotchner, A.E., 186
- on Hemingway depression, 186–187
- HR. *See* heart rate, ECT and
- HRSD. *See* Hamilton Rating Scale for Depression
- Hubbard, Lafayette Ronald, 211, 212, 213
- Church of Scientology under, 187, 208, 212
- Dianetics development by, 212
- Hughes, Ted, 184
- HVA. *See* homovanilic acid
- hyperventilation, 423, 480
- hypoactivity, from antipsychotic drugs, 372
- hypofrontality, 365–367
- apathetic syndrome in, 366
- behavioral/mental changes and, 366–367
- dysexecutive syndrome in, 366
- orbitofrontal syndrome in, 366
- somnolence and, 367
- hypomania, 535–536
- hypothesized mechanisms of action, for ECT, 75, 76–90. *See also* neurochemical theories
- abnormal metabolism in, 85
- GABA concentrations and, 85–86
- glutamate levels and, 85
- imaging studies for, 85–87
- anatomical theory of, 78
- direct stimulation hypothesis in, 78
- TMS in, 78
- anticonvulsant theory of, 78
- seizure thresholds in, 78
- background of, 75
- development of, 79–89
- electrical stimulation in, 82–89
- organizational levels of the brain in, 79–82
- diencephalic theory of, 77–78
- depression and, 77
- functional consequences of, 85–87
- for depression, 85
- neurochemical theories of, 75–77
- gene transcription in, 76–77
- intracellular signaling in, 76–77
- neurotransmitter theories in, 75–76
- neurotrophic action in, 76–77
- neuronal network function restoration in, 87–89
- seizure generalization theory and, 79, 89
- objections to, 79
- ICD-10. *See International Classification of Diseases, 10th Revision*
- ICDs. *See* implantable cardioverter defibrillators
- Iceland. *See* Scandinavia, ECT as treatment in
- ictal periods, 95
- EEG during, 469–472
- interpretation of, 471–472
- scalp distribution of, 471
- seizure duration during, 471
- seizure expression during, 471–472
- seizure rhythms during, 470
- neuroimaging in ECT during, 96–98
- electrode placement in, 97–98
- with PET, 97–98
- with SPECT, 96–97
- Impastato, David, 227
- implantable cardioverter defibrillators (ICDs), 405
- incapacity. *See* mental incapacity
- India, ECT use in, 258
- induction agents, for anesthesia, 415–418
- barbiturates, 415–416
- etomidate, 417
- inhalational, 418
- ketamine, 417–418
- propofol, 417
- thiopental, 416–417
- ultrashort-acting narcotics, 418
- informed consent, for ECT, xxv–xxvi, 384–398
- competency for, 393–394
- determination of, 393
- legally relevant criteria for, 395–396
- MacCAT-T for, 393
- court-ordered treatment and, 397
- PADs and, 397
- POA and, 397
- definitions of, 385

- informed consent, for ECT (*cont.*)
 discussion strategies for, 387–392
 for adverse side effects, 391
 APA Task Force report on, 392
 for consent process, 387–389
 for ECT v. other treatments, 389–390
 for nature of illness, 389
 physician's role in, 389
 for risk factors, 391–392
 for treatment/posttreatment, 389,
 390–391
- historical development of, 385
 in legal cases, 385
Parens Patriae doctrine and, 385
- hospital programs policy guidelines for,
 289–292
- in Latin America, 279–280
- legal applications of, 385–386
 in malpractice cases, 385
 State of California Welfare and Institutions
 Code for, 386
- legislation on, for ECT use, 215
 model for, 218
 in Texas, 216–217
- mental capacity for, 393–394
 determination of, 393
 legally relevant criteria for, 395–396
- mental incapacity and, 393–397
 National Quality Forum for, 394
- obstacles to, 392–397
 with competent patients, 392
 mental incapacity as, 393–397
 practical strategy methods for, 386–387
- Inglis, James, 174, 443
- Insane Liberation Front, 214
- The Insulin Myth*, 27
- insulin therapy, after coma inducement, 18,
 24–28
 ambulatory, 25
 application procedure for, 25
 with chemical convulsants, 28–30
 application procedures for, 29
 complications from, 29–30
 indications for, 29
 complications of, 28
 fatalities as, 28
 convulsive factor in, 33–34
 “dry shock” from, 33
 epileptiform phenomena in, 33
 glucagon in, 25
 historical background of, 24–25, 167–168
 indications for, 25–27
 “moist shock” from, 33
 outcomes from, 21
 patient fear of, 31–33
 remission rates with, 26
 for schizophrenia, 26, 167
 PZT v., 26
 as symptomatic, 27
- intelligence, 487–490
 WAIS for, 488
- interictal periods, 95
 neuroimaging, with ECT, 99–105
 with DTI, 105
 with DWI, 105
 HRSD scores and, 103
 with MRI, 104–105
 with MRS, 104
 with PET, 102
 with SPECT, 103–104
 with TCD, 102, 103
- intermittent tDCS, 581
- International Classification of Diseases, 10th
 Revision (ICD-10)*, 124
- International Coalition for the Abolition of
 Electroshock, 214
- International Congress of Psychiatry, 26–27
- intracellular signaling, 76–77
- intracranial space-occupying lesions, ECT with,
 409
- intramuscular medication, in pre-ECT protocol,
 xxv–xxvi
- Japan, ECT use in, 257–258
- Kalinowsky, Lothar, 169
- Karliner, William, 170
- Kesey, Ken, 172, 210
- ketamine, 417–418
- Kety, Seymour, 67
- Kf-1 gene, 64
- Kill Your Sons* (Reed), 187
- kindling, 7–8
- Klüver-Bucy syndrome, 430
- Kohloff, Roland, 208
- Korsakov, S.S., 272
- Lancaster, Neville, 173
- LART technique. *See* left anterior right temporal
 technique
- laryngeal mask airway (LMA), 422
- Latin America. *See also* Argentina, ECT use in;
 Brazil, ECT use in; Chile, ECT use in;
 Cuba, ECT use in; Mexico, ECT use in
- academic research in, 278
- demographics for, 277
- ECT use throughout, 276–283
 anesthesia with, 279
 applications of, 278–279
 history of use in, 276–277

- informed consent for, 279–280
 - rates of, 279
 - techniques for, 279
 - training for, 280
- geography of, 276
- mental health disorder rates in, 277–278
- scarcity of resources for, 277–278
- Lawson, J.S., 175
- l-dopa, 424
- left anterior right temporal (LART) technique,
 - 175, 441–442
 - clinical applications of, 441
 - MMSE scores after, 442
- legislation, for ECT use, 207–220
 - APA Task Force role in, 214–215
 - for banned use, 208
 - in California, 214–216
 - constructive lawmaking in, 218–219
 - films' influence on, 210–211
 - history of, 214–218
 - for informed consent, 215
 - model for, 218
 - in Texas, 216–217
 - litigation cases as basis for, 209–210
 - overregulation as result of, 210
 - in Massachusetts, 215
 - proactive, 219
 - in Texas, 216–218
 - for informed consent, 216–217
 - Texas Society of Psychiatric Physicians influence on, 216
- Leicestershire trial, 118, 449
- lesions. *See* intracranial space-occupying lesions, ECT with
- lethal catatonia, 350. *See also* malignant catatonia, ECT for
- Levant, Oscar, 183, 188, 194
- Lewis, Aubrey, 22
- Liberson, Wladimir, 170
- Lisanby, Sarah, 174
- lithium, 423–424
 - cECT with, for depression, 507
- litigation, over ECT use, 209–210
 - Aden v. Younger*, 210, 219
 - Mitchell v. Robinson*, 209
 - overregulation as result of, 210
 - “therapeutic privilege” as defense in, 209
 - Wyatt v. Hardin*, 209–210, 219
- LMA. *See* laryngeal mask airway
- Loach, Ken, 188
- LORETA. *See* low-resolution brain electromagnetic tomography
- Loudet, Osvald, 280
- Lowell, Robert, 181
- low-resolution brain electromagnetic tomography (LORETA), 96
 - during interictal period, with ECT, 103
- MacCAT-T. *See* McArthur Competence Assessment Tool for Treatment
- Madness and Civilization*. *See* *The History of Madness*
- magnetic resonance imaging (MRI), 94, 95–96
 - DTI, 94
 - fMRI, 96
 - during interictal period, with ECT, 104–105
- magnetic resonance spectroscopy (MRS), 94
 - during interictal period, with ECT, 104
- maintenance electroconvulsive therapy (MECT), 138–139, 518–522. *See also* continuation electroconvulsive therapy
 - for bipolar disorders, 511
 - cognitive function during, 521–522
 - CORE study on, 520
 - definition of, 518
 - effectiveness of, 520
 - electrode placement during, 522
 - NICE on, 519–520
 - pharmacotherapy with, 520–521
 - relapse rates for, 519
 - for schizoaffective disorders, 135
 - with stimulus dosing, 460–461, 522
- major depressive disorder (MDD), 489
 - VNS trials for, 547
- malarial-fever therapy, 167
- malignant catatonia, ECT for, 133–135
 - antipsychotic drugs v., 133
 - NMS and, 133
 - “shock-block” method of, 134
 - survival rates for, 134–135
- malpractice, ECT use and, 204
 - informed consent and, 385
 - psychiatric hospital programs and, 204
 - “therapeutic privilege” as defense against, 209
- mania
 - ECT for, 119–120
 - from TMS, as side effect, 535–536
 - TMS for, 531–532
- manic episodes, ECT for, 354
- Manning, Martha, 189–190
- Mayo Clinic, 317
- McArthur Competence Assessment Tool for Treatment (MacCAT-T), 393
- McGuire, Tobey, 190
- MDD. *See* major depressive disorder
- mECT. *See* maintenance electroconvulsive therapy
- medical insurance, ECT use and, 232–233

600 Index

- medications. *See* intramuscular medication; oral medications
- Meduna, Ladislav, 18, 168
- “Meduna’s method,” 266
- MEF2C genes, 63
- melancholia, diagnosis of, 347. *See also* depression
- delusions with, 352–353
- ECT for, 347–348, 351
- with multiple medications, 347–348
- SSRIs v., 347–348
- psychotic, 353
- Memoirs of an Amnesiac* (Levant), 183
- memory loss, 169. *See also* working memory
- after ECT, 490–493
- SSMQ for, 491
- subjective complaints of, 490–491
- EEG with ECT and, 472–473
- from electrode placement, 436
- from stimulus dosing, 454–455
- mental capacity, 393–394
- determination of, 393
- legally relevant criteria for, 395–396
- mental disorders
- ECT as treatment for, 89
- organizational levels of brain and, 80–82, 89
- structural abnormalities in, 81–82
- mental incapacity, 393–397
- National Quality Forum for, 394
- Mental Patients Liberation Project, 214
- “The Merry Pranksters,”
- Mexico, ECT use in, 281–282
- Meyer, Adolph, 18
- Meyers, Jeffrey, 186
- MI. *See* myocardial infarction, with ECT
- Mini Mental State Examination (MMSE), 435, 485–486
- after bifrontal electrode placement, 443–444
- after bitemporal electrode placement, 438
- after LART technique, 442
- minors, ECT use for, 294–295
- missed seizures, 473–474
- Mitchell v. Robinson*, 209
- mivacurium, 420
- MMSE. *See* Mini Mental State Examination
- Moench, Louis, 173
- “moist shock,” 33
- Molohov, A.I., 267
- monoamine hypothesis, 76
- monoamine systems
- depression from depletion of, 46
- hypothesis for, 76
- Montgomery-Asberg Depression Rating Scale, 346
- mood disorders, 76. *See also* antidepressant medications; depression
- chemical convulsive therapy for, 167
- depression
- brain stimulation applications for, 68
- diencephalic theory and, 77
- ECT for, 45, 109–120
- hippocampal volume and, 65–66
- HRSD for, 103
- monoamine depletion and, 46
- NE and, 49–51
- NPY neuropeptide and, 53
- PTZ for, in non-ECT therapy, 21–22
- serotonergic pathways and, 47–49
- ECT for, 109–120
- antidepressant medications v., 114–115, 117
- for mania, 119–120
- placebo trials v., 109–112, 114
- response rates for, 109, 110
- for subtypes of depression, 117–119
- variety of treatments in, 117
- mania, ECT for, 119–120
- symptoms of, 77–78
- Morgan, Robert F., 212
- Moscow Society of Neurologists and Psychiatrists, 270
- movement disorders, ECT with, 407–408
- PD, 407–408
- MRI. *See* magnetic resonance imaging
- MRS. *See* magnetic resonance spectroscopy
- Müller, Max, 18
- muscle relaxants, with ECT, 170. *See also* succinylcholine
- with anesthesia, 418–421
- cuff method, 419
- mivacurium, 420
- moderate/short-acting, 420–421
- succinylcholine, 419–420
- in Asia, 261–262
- development of, 418–419
- myocardial infarction (MI), with ECT, 404
- ACC/AHA guidelines for, 404
- medication treatment guidelines for, 404
- Myth of Mental Illness* (Szasz), 172
- NAPA. *See* Network Against Psychiatric Assault
- narcosis agents, xxvi–xxvii
- Nash, John, 211
- National Anti-Shock Action, 249
- National Institute for Clinical Excellence (NICE)
- ECT guidelines under, 240–241
- for children/adolescents, 499
- on MECT, 519–520

- pre-NICE standards and practices, in U.K., 238–240
- National Institute of Mental Health (NIMH), 208
- ECT usage, demographics for, 227
- National Institute of Neurological Disorders and Stroke (NINDS), 576
- National Quality Forum, 394
- NCS-1 neuropeptide, 53
- NE. *See* norepinephrine receptors
- Nelson, Alexander, 175, 441
- nerve growth factor (NGF) genes, 62
- NET. *See* norepinephrine transporter
- The Netherlands
- Dutch Association for Psychiatry in, 249
 - ECT in, 249–250
 - National Anti-Shock Action in, 249
- Network Against Coercive Psychiatry, 217
- Network Against Psychiatric Assault (NAPA), 214, 215
- neuritin gene, 61
- neurochemical theories, 75–77
- gene transcription in, 76–77
 - intracellular signaling in, 76–77
- neurotransmitter theories in, 75–76
- dopamine hypothesis in, 76
 - monoamine hypothesis, 76
- neurotrophic action in, 76–77
- neuroendocrine view. *See* diencephalic theory
- neurogenesis, after ECS, 64–66, 67
- regulation of, 65, 66–67
- neuroimaging, for ECT, 94–105
- with DTI, 94
 - during interictal period, 105
 - with DWI, 96
 - during interictal period, 105
 - with EEG, 96
 - future applications for, 105–106
 - during ictal period, 96–98
 - electrode placement in, 97–98
 - with PET, 97–98
 - with SPECT, 96–97 - during interictal period, 99–105
 - with DTI, 105
 - with DWI, 105
 - HRSD scores and, 103
 - with LORETA, 103
 - with MRI, 104–105
 - with MRS, 104
 - with PET, 102
 - with TCD, 102, 103
 - with LORETA, 96
 - during interictal period, 103 - measurement parameters for, 95–96
 - with MRI, 94, 95–96
 - DTI, 94
 - fMRI, 96
 - during interictal period, 104–105 - with MRS, 94
 - during interictal period, 104 - with PET, 94
 - during ictal period, 97–98
 - during interictal period, 102 - during postictal periods, 99–101
 - purpose of, 94–95
 - with SPECT, 94
 - during ictal period, 96–97
 - during interictal period, 103–104 - structural abnormalities under, 94
 - with TCD, 96
 - during interictal period, 102, 103
- neuroleptic malignant syndrome (NMS), 133
- from antipsychotic drugs, 371
- neuropeptides, ECT effects on, 52–54
- in animal models, 52
- NCS-1, 53
- neuroserpin, 53
- neurotensin, 54
- NPY, 52–53
- angiogenic patterns of, 53
 - after chronic ECS, 53
 - depression and, 53
- tachykinins, 54
- after chronic ECS, 54
- neuroserpin neuropeptide, 53
- neurotensin neuropeptide, 54
- neurotransmitters, ECT effects on, 46–52
- depression and, 46
 - dopaminergic pathways, 51
 - dopamines, 51 - GABA pathways, 46, 51–52
 - ECS and, 51–52
 - ECT and, 51–52 - glutamergic systems, 52
 - EAAC1, 52 - noradrenergic pathways, 49–51
 - depression and, 49–51
 - NE receptors, 49–51 - serotonergic pathways
 - depression and, 47–49
 - serotonins in, 47–49
- neurotransmitter theories, 75–76
- dopamine hypothesis in, 76
 - monoamine hypothesis, 76
- neurotrophic action, 76–77
- New England Journal of Medicine*, 174
- Newsweek*, 191
- NGF genes. *See* nerve growth factor genes

602 **Index**

- NICE. *See* National Institute for Clinical Excellence
- NIMH. *See* National Institute of Mental Health
- NINDS. *See* National Institute of Neurological Disorders and Stroke
- NMS. *See* neuroleptic malignant syndrome
- N-Myc downstream-regulated protein 2 (Ndr2) gene, 64
- nonelectrical convulsive (non-ECT) therapies, 17–37. *See also* chemical convulsants; insulin therapy, after coma inducement; pentamethylenetetrazol, in non-ECT therapy
- for bipolar disorders, 36–37
- chemical convulsants, 18–24
- ECT as replacement for, 23–24
- with insulin therapy, 28–30
- PM-1090, 24
- PTZ as, 19–24
- flurothyl inhalation, 30–31
- application procedures for, 30
- complications from, 30–31
- historical background for, 30
- indications for, 30
- seizure onset with, 30
- historical background of, 17–18
- Meduna role in, 18
- in mental institutions, 17
- psychiatrists as eugenicists and, 17
- insulin therapy, after coma inducement, 18, 24–28
- ambulatory, 25
- application procedure for, 25
- with chemical convulsants, 28–30
- complications of, 28
- convulsive factor in, 33–34
- “dry shock” from, 33
- epileptiform phenomena in, 33
- glucagon in, 25
- historical background of, 24–25
- indications for, 25–27
- “moist shock” from, 33
- outcomes from, 21
- remission rates with, 26
- for schizophrenia, 26
- as symptomatic, 27
- PTZ, 19–24
- application procedure for, 19–20
- complications from, 22–23
- for depression, 21–22
- ECT replacement for, 23–24
- indications for, 20–22
- outcomes from, 21
- outcome treatments from, 21
- patient fear of, 31–33
- psychological impact from, 32–33
- relapse rates for, 21
- remission rates from, 20–21
- for schizophrenia, 20–21
- theoretical implications of, 31–37
- patient fear as, 31–33
- psychological impacts in, 32–33
- nonpsychiatric physicians. *See* physicians, nonpsychiatric
- noradrenergic pathways, 49–51
- depression and, 49–51
- NE receptors, 49–51
- norepinephrine (NE) receptors, 49–51
- ECS and, 50–51
- ECT effects on, 50–51
- NET and, 49
- norepinephrine transporter (NET), 49
- Northwick Park trial, 113, 118, 449
- Norway. *See* Scandinavia, ECT as treatment in
- NPY neuropeptide, 52–53
- angiogenic patterns of, 53
- after chronic ECS, 53
- depression and, 53
- nursing guidelines, for ECT treatment, 300–306
- inpatient transportation, 301–302
- in physical suite, 322–323
- for post-ECT duties, 305–306
- pre-ECT patient preparation, 301
- for recovery procedures, 304–305
- in recovery room, 324–325
- staff assistance during treatment, 303–304
- treatment room preparation, 302
- obsessive-compulsive disorder (OCD), 343
- DBS for, 562
- studies for, 564
- neurobiology of, 560
- tardive, 368
- TMS for, 532–533
- OCD. *See* obsessive-compulsive disorder
- One Flew over the Cuckoo's Nest*, xviii, 172, 188, 191, 192, 210, 321
- On the Sea of Memory* (Cott), 190–191
- oral medications, in pre-ECT protocol, xxvi
- orbitofrontal syndrome, 366
- from ECT, 367
- organic catatonia, ECT for, 139–141
- Ottosson, Jan-Otto, 172, 238
- Out of Tune* (Helfgott), 193
- oxytocin, 158–159
- pacemakers, 405
- Pacheco e Silva, Antonio Carlos, 282
- PADs. *See* psychiatric advance directives
- PAHO. *See* Pan American Health Organization

- Pakistan, ECT use in, 258
- Pan American Health Organization (PAHO), 277
- panic disorder, 533
- PANSS. *See* Positive and Negative Syndrome Scale
- Parens Patriae* (father of his country) doctrine, 385
- Parkinson's disease (PD)
DBS for, 557
ECT with, 407–408
 l-dopa and, 424
 tDCS for, 579
- Pascal, Constance, 167
- PD. *See* Parkinson's disease
- peak heart rate, ECT and, 479–481
 Benchmark Method for, 479, 481
 hyperventilation from, 480
- pentylentetrazol (PTZ), in non-ECT therapy, 19–24, 168
 application procedure for, 19–20
 patient distress in, 19–20
 seizure generation from, 19
 complications from, 22–23
 fatalities from, 22
 neuropathologic, 22–23
 seizure severity as, 23
 for depression, 21–22
 ECT replacement for, 23–24
 indications for, 20–22
 illness duration and, 20
 outcomes from, 21
 patient fear of, 31–33
 psychological impact from, 32–33
 relapse rates for, 21
 remission rates from, 20–21
 for schizophrenia, 20–21
 insulin therapy v., 26
- PET. *See* positron emission tomography
- phenytoin, 35
- physical suite layout, for ECT, 314–321
 anesthetists in, 323–324
 design considerations for, 321
 for high-volume operations, 316
 IV access considerations in, 317–319
 nurses in, 322–323
 outpatient considerations for, 319
 pretreatment personnel in, 322
 psychiatrists in, 323
 for recovery rooms, 320–321
 nurses in, 324–325
 in small hospitals, 315–316
 for small-volume operations, 315–316
 surgical operating rooms and, 314
 for treatment rooms, 319–320
- physical therapies, 167. *See also*
 electroconvulsive therapy
 chemical convulsive, 167
 insulin, for schizophrenia, 26, 167
 malarial-fever therapy, 167
 physicians, nonpsychiatric, ECT training for, 199
- placebo trials
 ECT v., for mood disorders, 109–114, 111–112
 anesthesia induction and, 113–114
 HRSD scores in, 110–113
 Northwick Park trial, 113, 118, 449
 Leicestershire Trial, 118, 449
- Plath, Sylvia, 184–185, 188, 211, 413
- Ploticher, A.I., 268
- PM-1090. *See* tetramethyl-succinamide pneumonia. *See* aspiration pneumonia
- POA. *See* power of attorney
- Portugal, ECT use in, 250–251
- Positive and Negative Syndrome Scale (PANSS), 530
- positron emission tomography (PET), 94
 during ictal period, with ECT, 97–98
 during interictal period, with ECT, 102
 VNS under, 544
- posterior pituitary hormones, after ECT, 158–159
 oxytocin, 158–159
 vasopressin, 158–159
- postictal confusion/disorientation, 486–487
- postictal excitement, 150–151
 prevention methods for, 150–151
- postictal periods, 95
 EEG during, 470–471
 neuroimaging during, with ECT, 99–101
- post-traumatic stress disorder (PTSD), xviii, 345
 TMS for, 532
- power of attorney (POA), 397
- prefrontal model. *See* anatomical theory
- pregnancy
 ECT during, 409
 hormones production during, 151
 VNS during, 550
- private hospitals, ECT use in, 230. *See also*
 psychiatric hospital programs, ECT in
 prolactin release, from ECT, 152, 153–158
 AUC and, 156
 basic model for, 156–157
 brain neurochemistry changes and, 154
 as pituitary hormone archetype, 154–155
 seizure-induced, 158
- propofol, 417
- psychiatric advance directives (PADs), 397

604 **Index**

- psychiatric hospital programs, ECT in, 201. *See also* nursing guidelines, for ECT treatment
 under EMTALA, 287
 under FDA, 287
 malpractice concerns with, 204
 at Mayo Clinic, 317
 model policy guidelines for, 287–294, 313
 for convulsive treatment, for involuntary patients, 293–294
 for convulsive treatment, for voluntary patients, 292–293
 departmental performance improvements under, 311–312
 development for, 287–288
 for excessive use of convulsive treatment, 296
 general, 298–299
 for informed consent, 289–292
 for inpatients from other facilities, 306–308
 for minors, 294–295
 monthly reports under, 296–297
 nursing responsibilities in, 300–306
 for outpatients, 299–300
 posttreatment audit committees in, 295–296
 quality assurance monitors under, 312–313
 for regional centers, 308–311
 scope of service under, 311
 violation penalties under, 298
 for patients from other facilities, 306–308
 for medical emergencies, 308
 posttreatment/recovery for, 307–308
 pretreatment for, 306–307
 treatment for, 307
 public v. private, 230
 in small hospitals, 315–316
 in UIHC, 317
 psychiatrists, 323
 anesthetists and, 324, 424–425
 CME for, 205
 ECT and, response toward, 197–205
 legislative regulations against, 202–204
 malpractice concerns, 204
 as molded by negative film portrayals, 198
 as professional mindset, 204–205
 sociopolitical barriers to, 201–202
 training issues with, 199–200
 in treatment patterns, 198, 200–201
 in U.S., 198–199
 as eugenicists, 17
 portrayals of, in films, 210
 residency training for, 199–200
 under ACGME, 199–200
 organizational recommendations for, 200
- psychiatry
 Church of Scientology and, 212
 Dianetics as alternative to, 213
 in Russian Federation, under Stalin, 267
Psychobiology of Convulsive Therapy, 68
 psychopharmacology, 172
 antipsychotic drugs, xvii
 for acute schizophrenia, 127–128
 for chronic schizophrenia, with ECT, 136–138
 for malignant catatonia, 133
 psychosis, ECT for, 350
 medication-resistant, 354–357
 chronic, 356–357
 intermediate-duration, 355–356
 schizoaffective illness and, 355
 schizophrenia diagnosis v., 356–357
 tardive, 367–369
 psychotic disorders. *See* catatonia; schizophrenia
 psychotic melancholia, 353
 PTSD. *See* post-traumatic stress disorder
 PTZ. *See* pentamethylenetetrazol, in non-ECT therapy
 public hospitals, ECT use in, 230. *See also* psychiatric hospital programs, ECT in
- race, ECT use and, 232
 Ramirez Moreno, Samuel, 281
 reboot theory, of ECT, xxiii–xxv
 anticonvulsant activity in, xxv
 preexisting psychiatric illness in, xxiii
 seizures' role in, xxiii
 grand mal, xxiii–xxiv
 neurotransmitter depletion/replenishment, xxiv–xxv
 receptors, effects of ECT on, 46–52
 depression and, 46
 dopamine, 51
 NE, 50–51
 serotonins, 47–49
 5-HT, 47–49
 Reed, Lou, 187
 regional medical centers, ECT guidelines for, 308–311
 reporting requirements for, 311
 resting hypercortisolism, 159
 cognitive side effects of, 160
 depression and, 160
 HRSD scores and, 160
 retrograde amnesia, 491–492
 right unilateral electrode placement, 439–441
 bitemporal v., 440
 clinical application of, 439
 dosing levels for, 440–441
 rationale for, 439

- rocuronium, 421
- Rosenberg, Leon, 208
- Rotshtein, G.A., 266
- Rozhnov, V.A., 433
- Rubio y Yarza, Mauricio, 281
- Russian Federation, ECT use in, 266–273
- anti-ECT movement in, 268
 - chemical convulsants and, in early use of, 266
 - contemporary applications of, 271–272
 - device development in, 271
 - early history of, 266–270
 - “Meduna’s method” and, 266
 - Moscow Society of Neurologists and Psychiatrists in, 270
 - for nonpsychiatric conditions, 272
 - political influence on, 267–268
 - psychiatry in, under Stalin, 267
 - Soviet Scientific Society of Neurologists and Psychiatrists in, 268
- Sackeim, Harold, 173, 174
- Sakel, Manfred, 18, 167–168
- SAPS. *See* Simplified Acute Physiology Scores
- Scandinavia, ECT as treatment in, 236–238
- anti-ECT movement in, 237
 - future applications for, 243
 - history of, 236
 - rates of use for, 236–237
 - research tradition and, 238
 - training for, 242
- schizoaffective disorders, ECT for, 135–136
- psychosis and, 355
- schizophrenia. *See also* catatonia
- acute, ECT for, 127–131
 - antipsychotic drugs v., 127–128
 - remission rates for, 127
 - trial studies for, 128–130, 131
 - catatonia and, 124
 - acute, 131–133
 - organic, 139–141
 - cECT for, 511
 - chronic, ECT for, 136–138
 - antipsychotic drugs and, 136–138
 - definition of, 136
 - effect of catatonic features after, 138
 - diagnosis rates for, in Europe, 22
 - ECT for, 124–131, 142
 - for acute schizophrenia, 127–131
 - in Asia, 259–260
 - for chronic schizophrenia, 136–138
 - continuation, 138–139
 - history of, 124–125
 - mECT and, 135, 138–139
 - methodological limitations of, 125–126
 - for schizoaffective disorders, 135–136
 - for schizophreniform disorder, 126–127
 - epilepsy and, 34–35
 - eugenics as answer to, 17
 - homeostatic theory of, 35
 - insulin therapy for, 26
 - PZT v., 26
 - medication-resistant chronic psychosis v., 356–357
 - medication-resistant intermediate-duration psychosis v., 355–356
 - pharmacological treatments for, 126
 - PTZ for, in non-ECT therapy, 20–21
 - TMS for, 36, 530–531
 - with auditory hallucinations, 530
 - Auditory Hallucinations Rating Scale for, 530
 - with catatonia, 531
 - with negative symptoms, 531
 - PANSS for, 530
 - SAPS for, 530
- schizophreniform disorder, 126–127
- ECT for, 126–127
- Scotland. *See* United Kingdom, ECT as treatment in
- seizure generalization theory, 79, 89
- objections to, 79
- seizures. *See also* ictal periods; interictal periods
- abortive, 474
 - in anticonvulsant theory, thresholds for, 78
 - Benchmark Method and, morphology of, 457–458
 - in children/adolescents, thresholds for, 501
 - tardive, 502
 - curare and, 23
 - ECT and, repeated application complications for, 35–36
 - electricity and, in generation of, 6–8, 82
 - depolarization and, 7
 - kindling and, 7–8
 - epileptic v. electrically induced, 84
 - epileptiform phenomena, 33
 - from flurothyl inhalation therapy, 30
 - forced normalization between, 35
 - generalization theory for, 79
 - objections to, 79
 - grand mal, xxiii–xxiv
 - from CNS depletion, xxiii
 - HR and, 477–479
 - CRH and, 478
 - EEG recording of, 479
 - epinephrine and, 478
 - neuroanatomic rationale for, 477–478

606 **Index**

- seizures (*cont.*)
 ictal periods for, 95
 EEG during, 469–472
 neuroimaging in ECT during, 96–98
 interictal periods for, 95
 neuroimaging, with ECT, 99–105
 missed, 473–474
 neuronal network function restoration and, 87–89
 postictal periods for, 95
 neuroimaging during, with ECT, 99–101
 prolactin release from, 158
 prolonged, 474
 from PTZ, in non-ECT therapy, 19
 increased severity of, 23
 repeated application complications from, 35–36
 in reboot theory, of ECT, xxiii
 neurotransmitter depletion/replenishment, xxiv–xxv
 spontaneous, 34
 ECT-generated v., 82–84
 from TMS therapy, 535
selective serotonin reuptake inhibitors (SSRIs)
 with antipsychotic drugs, 375–376
 for anxiety disorders, 342
 ECT v., for melancholia, 347–348
 electrode placement and, 433
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 556
Sereysky, M.Y., 272
serotonergic pathways
 depression and, 47–49
 serotonins in, 47–49
serotonins, 47–49
 ECS and, 47–49
 5-HT, 47–49
Shadowland (Arnold), 192
Shakespeare, William, 384
Shepherd, Michael, 238
Shine, 193
“shock-block” method, of ECT, 134
Shock: The Healing Power of Electroconvulsive Therapy (Dukakis), 191, 212
shock therapies, 167. *See also* physical therapies
Shock Treatment is Not Good for Your Mind (Friedberg), 211
Simmons, Everett, 341
Simplified Acute Physiology Scores (SAPS), 530
sine wave stimulus dose, 11
 brief pulse v., 12–13
single photon emission computed tomography (SPECT), 94
 during ictal period, with ECT, 96–97
 during interictal period, with ECT, 103–104
skin burns, from constant current stimulus generators, 4–5
skull bones, electrode placement and, neurobiology of, 437
Small, Iver, 173
The Snake Pit, 172
Spain, ECT use in, 251
SPECT. *See* single photon emission computed tomography
spinal cord injury, ECT with, 410
spontaneous seizures, 34, 82–84
Squire Subjective Memory Questionnaire (SSMQ), 491
SSMQ. *See* Squire Subjective Memory Questionnaire
SSRIs. *See* selective serotonin reuptake inhibitors
STAR*D study. *See* Sequenced Treatment Alternatives to Relieve Depression study
State of California Welfare and Institutions Code, for informed consent, 386
state regulations. *See* U.S. state regulations, against ECT use
stimulus dose method, xxviii
 brief pulse, 9–11
 approximation of separation in, 9
 electrode placement with, 10–11
stimulus dosing, with ECT, 447–463
 augmentation strategies for, 458–459
 Benchmark Method for, 456–458
 cardiovascular reactivity in, 458
 seizure morphology in, 457–458
 case studies of, 461–463
 cognitive side effects of, 454–455
 memory loss as, 454–455
 from sine wave stimulus, 455
 for depression, 450–454, 455–456
 with fixed dosing, 454
 with formula-based dosing, 453–454
 mECT and, 460–461
 with titrated dosing, 450–453
 electrode placement and, 459–460
 with mECT, 460–461, 522
 schedule for, 452
 sham studies for, 449
 units of measure for, 447–449
 waveform morphology for, 449–450
stimulus generators
 constant current, 4, 4–5
 skin burns from, 4–5
 constant voltage, 4
 fixed-charge, 4
stimulus potentiation, caffeine and, xxix
Stone, Alan, 210

- succinylcholine, 419–420
 metabolization of, 420
 side effects of, 419–420
- suicidality, depression and, 348
- surgery, ECT analogous to, xviii
- Swartz, Conrad, 171, 175
- Sweden. *See* Scandinavia, ECT as treatment in
- synaptic plasticity, after ECS, 64–66, 67
 neurotrophic factors for, 64–67
 structural changes, 65
- Szasz, Thomas, 172
- tachykinin neuropeptides, 54
 after chronic ECS, 54
- tachykinins neuropeptide, 54
- Taiwan, ECT use in, 256–257
- tardive dyskinesia, 370
- tardive OCD, 368
- tardive psychosis, 367–369
 ECT for, 369
- tardive seizures, 502
- Taylor, Michael, 175
- TCD. *See* transcranial Doppler
- tDCS. *See* transcranial direct current stimulation
- TDMHMR. *See* Texas Department of Mental Health and Mental Retardation
- The Tender Place* (Hughes), 184
- tetramethyl-succinamide (PM-1090), 24
- Texas Department of Mental Health and Mental Retardation (TDMHMR), 217
- Texas National Association of Women, 218
- Texas Society of Psychiatric Physicians, 216
- Thailand, ECT use in, 257
- theophylline, 424
- “therapeutic privilege,” 209
- Thesleff, Stephan, 413
- Thesleff, Stephen, 170
- thiopental, 416–417
- Thoreau, Henry David, 393
- thyrotropin-releasing hormone (TRH), 63
- Tierney, Gene, 183–184
- TIMP-1. *See* tissue inhibitors of metalloproteinases-1
- tinnitus, 533–534
- tissue inhibitors of metalloproteinases-1 (TIMP-1), 63
- titrated stimulus dosing, 450–453
- TMS. *See* transcranial magnetic stimulation
- training, for ECT, 199–200
 in Asia, 262–263
 in France, 248
 in Latin America, 280
 for nonpsychiatric physicians, 199
 during psychiatric residency, 199–200
 for psychiatrists, 199–200
- in Scandinavia, 242
- in UK, 242–243
- transcranial direct current stimulation (tDCS), 573–581
 advantages of, 575
 adverse effects of, 575–576
 for anxiety disorders, 580
 clinical applications for, 576–580
 clinical technique for, 573–575
 for craving disorders, 578–579
 for depression, 576–577
 electrode placement options in, 575
 for epilepsy, 577–578
 for fibromyalgia, 577
 future applications of, 581
 history of, 573
 intermittent v. constant-current, 581
 for PD, 579
 safety of, 576
 for working memory, 579–580
- transcranial Doppler (TCD), 96
 during interictal period, with ECT, 102
- transcranial magnetic stimulation (TMS), 525–537, 573
 adverse effects of, 535–536
 delusions, 536
 hypomania/mania, 535–536
 seizure induction, 535
 in anatomical theory, 78
 for bipolar mania, 531–532
 contraindications to, 536
 deep, 536–537
 for depression, 528–529
 bipolar, 530
 high-frequency, 529
 low-frequency, 529
 for dysthymic order, 530
 ECT v., 36, 534–535
 neurobiological background for, 527–528
 for OCD, 532–533
 for panic disorder, 533
 for PTSD, 532
 for schizophrenia, 36, 530–531
 with auditory hallucinations, 530
 Auditory Hallucinations Rating Scale for, 530
 with catatonia, 531
 with negative symptoms, 531
 PANSS for, 530
 SAPS for, 530
 for tinnitus, 533–534
- treatment-resistant depression, 172–173
 DBS for, 556
 in DSM-IV-TR, 549
 VNS for, 543, 549

- TRH. *See* thyrotropin-releasing hormone
- Tye, Larry, 191, 212
- UIHC. *See* University of Iowa Hospitals and Clinics
- UK *See* United Kingdom, ECT as treatment
ultra-brief pulse stimulus dose, 14–15
electrode placement with, 14–15
- United Kingdom (UK), ECT as treatment in, 238–242
contemporary standards and practices for, ECTAS within, 241
ECT Handbook in, 239, 241–242
future applications for, 243
under NICE, 240–241
pre-NICE standards and practices, 238–240
training for, 242–243
- United States (U.S.). *See also* legislation, for ECT use
ECT use in, 198–199, 209–210, 227–234
academic medical centers as factor for, 229
age as factor for, 231
APA guidelines for, 228
demographic variation in, 231–232
for depression, 228–229
ethnicity/race as factor in, 232
future applications for, 233–234
gender as factor in, 231–232
inpatient v. outpatient status and, 230–231
insurance access as factor for, 232–233
litigation over, 209–210
overuse of, 209
in public v. private hospitals, 230
regional/state variation for, 229
service sites for, 230–231
service system variation for, 229–230
small-area analysis for, 228–229
socioeconomic factors for, 232–233
usage trends for, 227
variation of, 228
- EMTALA in, 287
- legislation, for ECT use in, 207–220
APA task force role in, 214–215
for banned use, 208
in California, 214–216
constructive lawmaking in, 218–219
films' influence on, 210–211
history of, 214–218
for informed consent, 215
litigation cases as basis for, 209–210
in Massachusetts, 215
proactive, 219
in Texas, 216–218
state regulations in, against ECT use, 202–204
in Texas, 202–203
- University of Iowa Hospitals and Clinics (UIHC), 317
- Uruguay, ECT use in, 282
APA guidelines for, 282
- U.S. state regulations, against ECT use, 202–204, 233
antipsychiatry groups' influence on, 203–204
APA guidelines in, 202
in Texas, 202–203
- vagus nerve, 543
- vagus nerve stimulation (VNS) therapy, 543–553
adverse effects of, 551–552
antidepressant medications and, as alternative to, 549
application guidelines for, 549–552
ECT with, 549–550
parameter settings in, 550–551
for patient safety, 551
for patient selection, 549–550
for depression, 546–548
clinical outcomes for, 547
MDD, 547
trial studies for, 547–548
for epilepsy, 543, 546
future applications for, 552
indications for, 546–549
mechanisms of action for, 543–544
neurochemical changes from, 544
neurophysiological changes from, 543–544
under PET, 544
during pregnancy, 550
under SPECT, 544
surgical implant procedure for, 544–545
Therapy Pulse Generator in, 544–546
device parameters for, 550
programming for, 545–546
therapy system for, 544–546
for treatment-resistant depression, 543, 549
valvular disease, ECT with, 406
- VAMP2 gene. *See* vesicle-associated membrane protein gene
- vascular disease, ECT with, 405–406
- vasopressin, 158–159
- Vedak, Chandra, 171
- VEGF genes, 62
- vesicle-associated membrane protein (VAMP2) gene, 64
- Vesl/homer gene, 60–61
- VGf genes, 62
- VNS. *See* vagus nerve stimulation therapy
- VNS Therapy Pulse Generator, 544–546
device parameters for, 550
programming for, 545–546
- von Meduna, Ladislav, 246

Cambridge University Press

978-0-521-88388-7 - Electroconvulsive and Neuromodulation Therapies

Edited by Conrad M. Swartz

Index

[More information](#)

von Meduna, Lazlo, 282

WAIS. *See* Wechsler Adult Intelligence ScaleWales. *See* United Kingdom, ECT as treatment
in

Ward, Mary Jane, 172

Weiner, Richard, 173

Wechsler Adult Intelligence Scale (WAIS), 488

Wilcox, Paul, 170

Wilder, Gene, 184

Witton, Kurt, 172

working memory, 579–580

World Association of Electroshock Survivors,
217

World Psychiatric Association, 412

Wyatt v. Hardin, 209–210, 219